Oxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
Jenner Institute, University of Oxford - Old Road Campus, Oxford, UK.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2203023. doi: 10.1080/21645515.2023.2203023.
In early 2020, adult volunteers were invited to participate in a first-in-human trial of the COVID-19 vaccine, ChAdOx1 nCoV-19, in the United Kingdom (UK) at the height of the global pandemic when there was uncertainty regarding vaccine efficacy and side-effects. We conducted a retrospective survey of these uniquely situated individuals to gain insight into their views about the risks, motivations, and expectations of the trial and potential vaccine deployment. Our data from 349 respondents show that these volunteers were educated to a high-level with a clear understanding of the seriousness of the COVID-19 pandemic, as well as an appreciation of the role of science and research in developing a vaccine to address this global problem. Individuals were primarily motivated with altruistic intent and expressed a desire to contribute to the scientific effort. Respondents appreciated that their participation was associated with risk but appeared comfortable that this risk was low. Through our analysis, we highlight these individuals as a group with strong levels of trust in science and a sense of societal responsibility, and therefore are a potential valuable resource to improve confidence in novel vaccines. Vaccine trial participants could offer a credible collective voice to support positive messaging around vaccination.
2020 年初,正值全球大流行之际,人们对疫苗的疗效和副作用存在不确定性,英国邀请成年志愿者参与 COVID-19 疫苗 ChAdOx1 nCoV-19 的首次人体试验。我们对这些特殊情况下的个体进行了回顾性调查,以深入了解他们对试验风险、动机和预期以及潜在疫苗接种的看法。我们从 349 位受访者那里获得的数据表明,这些志愿者接受了高水平的教育,对 COVID-19 大流行的严重性有清晰的认识,并赞赏科学和研究在开发疫苗以解决这一全球性问题中的作用。志愿者主要是出于利他主义的动机,并表示希望为科学努力做出贡献。受访者认识到他们的参与存在风险,但似乎认为风险很低。通过我们的分析,我们将这些人作为一个群体,他们对科学有很强的信任度和社会责任感,因此是提高对新型疫苗信心的潜在有价值资源。疫苗试验参与者可以提供一个可信的集体声音,支持围绕接种疫苗的积极信息。
Hum Vaccin Immunother. 2023-12-31
BMJ Glob Health. 2022-2
Hum Vaccin Immunother. 2022-12-31
Science. 2018-3-9